More Stories

Informist, Friday, Dec. 19, 2025

 

--Cipla signs exclusive supply, marketing agreement for Pfizer s brands 

--Cipla to sell Pfizer's Corex, Dolonex, Neksium, Dalacin C for 5 years 

--Cipla: No upfront consideration paid or received as part of pact with Pfizer '

 

MUMBAI – Cipla Ltd. has entered into an agreement with Pfizer Ltd. and Pfizer Products India Pvt. Ltd. to market, distribute, and sell four products of Pfizer in India for five years, according to an exchange filing Friday. These products are cough syrup Corex, anti-inflammatory drug Dolonex, proton pump inhibitor Neksium, and antibiotic medicine Dalacin C.

 

Pfizer will manufacture, source, and supply the four products. No upfront consideration has been paid or received by the two parties as part of the agreement, both said in separate notices.

 

Pfizer said the said agreement would lead to a certain reduction in the company's field force, whom it would support during their career transition. The company said it will disclose the financial impact on account of reduction in employees in the upcoming financial results.

 

For the quarter ended September, Cipla had reported a consolidated net profit of INR 13.51 billion on a revenue of INR 75.89 billion. For the same quarter, Pfizer had reported a net profit of INR 1.89 billion on a revenue of INR 6.42 billion. At 1336 IST, shares of Cipla were up 0.7% at INR 1,509.20 on the National Stock Exchange, while shares of Pfizer were down 0.4% at INR 5,080.30.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Reported by Anshul Choudhary

Edited by Ashish Shirke

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.